Finoriq research workspace
Akari Therapeutics Plc (AKTX) SEC Filings & Filing Highlights
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for. Review AKTX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
- Company
- Akari Therapeutics Plc (AKTX)
- Ticker
- AKTX
- Market Cap
- $19.1M
- Latest Price
- $10.89
- Industry
- Biotech & Pharma
Akari Therapeutics Plc (AKTX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Akari Therapeutics Plc (AKTX).
| Event | Form | Date |
|---|---|---|
| The voting results below are final and reported in ordinary sharesOn June 30, 2026, Akari Therapeutics, Plc (the “Company”) held its Annual General Meeting. Proxies were solicited pursuant to the Company’s... | 8-K5.07 | 2026-07-02 |
| Akari Therapeutics Plc: Material agreementAs previously disclosed on its Current Report on Form 8-K on May 22, 2026, Akari Therapeutics, Plc (the “Company”) entered into a securitie... | 8-K1.01 | 2026-06-26 |
| The information under Item 1.01 of this Current Report on Form 8-K regarding the unregistered s...The information under Item 1.01 of this Current Report on Form 8-K regarding the unregistered securities described herein is incorporated h... | 8-K3.02 | 2026-05-22 |
| Akari Therapeutics Plc: Material agreementOn May 20, 2026, Akari Therapeutics, Plc (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certa... | 8-K1.01 | 2026-05-22 |
| Akari Therapeutics Announces ADS Ratio ChangeAkari Therapeutics Announces ADS Ratio Change | 8-K7.01 | 2026-03-17 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.